PD 190497
Alternative Names: CI 1029Latest Information Update: 23 Jul 2002
Price :
$50 *
At a glance
- Originator Pfizer
- Class Antivirals
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 07 Jul 2000 New profile
- 07 Jul 2000 Preclinical development for HIV infections treatment in USA (Unknown route)